Man Group
GLUE icon

Man Group’s Monte Rosa Therapeutics GLUE Stock Holding History

Man Group’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$416K Buy
25,262
+8,950
+55% +$171K ﹤0.01% 2130
2025
Q4 		$256K Sell
16,312
-24,263
-60% -$327K ﹤0.01% 2070
2025
Q3 		$301K Buy
40,575
+4,184
+11% +$22.2K ﹤0.01% 2002
2025
Q2 		$164K Buy
+36,391
New +$162K ﹤0.01% 2097

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Man Group's GLUE Position: Q1 2026 in Review

Man Group increased its Monte Rosa Therapeutics (GLUE) stake by 55% in Q1 2026, buying an estimated $171K and bringing the position to 25,262 shares worth $416K. The position accounts for ﹤0.01% of the portfolio, ranked #2130.

Man Group first reported a position in GLUE in Q2 2025 and has held it in 4 quarters since. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Man Group held 25,262 shares of Monte Rosa Therapeutics worth $416K as of Q1 2026.
  • Man Group bought 8,950 Monte Rosa Therapeutics shares in Q1 2026, an estimated $171K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Man Group's portfolio in Q1 2026, its #2130 holding.
  • Man Group first reported a position in Monte Rosa Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.